312 related articles for article (PubMed ID: 19223625)
41. Targeting the dengue β-OG with serotype-specific alkaloid virtual leads.
Gangopadhyay A; Chakraborty HJ; Datta A
J Mol Graph Model; 2017 May; 73():129-142. PubMed ID: 28279821
[TBL] [Abstract][Full Text] [Related]
42. Antiviral activity of chondroitin sulphate E targeting dengue virus envelope protein.
Kato D; Era S; Watanabe I; Arihara M; Sugiura N; Kimata K; Suzuki Y; Morita K; Hidari KI; Suzuki T
Antiviral Res; 2010 Nov; 88(2):236-43. PubMed ID: 20851716
[TBL] [Abstract][Full Text] [Related]
43. Identification and characterization of new potent inhibitors of dengue virus NS5 proteinase from Andrographis paniculata supercritical extracts on in animal cell culture and in silico approaches.
Kaushik S; Dar L; Kaushik S; Yadav JP
J Ethnopharmacol; 2021 Mar; 267():113541. PubMed ID: 33152438
[TBL] [Abstract][Full Text] [Related]
44. Small-Molecule Fusion Inhibitors Bind the pH-Sensing Stable Signal Peptide-GP2 Subunit Interface of the Lassa Virus Envelope Glycoprotein.
Shankar S; Whitby LR; Casquilho-Gray HE; York J; Boger DL; Nunberg JH
J Virol; 2016 Aug; 90(15):6799-807. PubMed ID: 27194767
[TBL] [Abstract][Full Text] [Related]
45. Identification of Ebola Virus Inhibitors Targeting GP2 Using Principles of Molecular Mimicry.
Singleton CD; Humby MS; Yi HA; Rizzo RC; Jacobs A
J Virol; 2019 Aug; 93(15):. PubMed ID: 31092576
[TBL] [Abstract][Full Text] [Related]
46. Envelope proteins as antiviral drug target.
Verma J; Subbarao N; Rajala MS
J Drug Target; 2020 Dec; 28(10):1046-1052. PubMed ID: 32643453
[TBL] [Abstract][Full Text] [Related]
47. High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease.
Balasubramanian A; Manzano M; Teramoto T; Pilankatta R; Padmanabhan R
Antiviral Res; 2016 Oct; 134():6-16. PubMed ID: 27539384
[TBL] [Abstract][Full Text] [Related]
48. Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase.
Xu HT; Colby-Germinario SP; Hassounah S; Quashie PK; Han Y; Oliveira M; Stranix BR; Wainberg MA
Antimicrob Agents Chemother; 2016 Jan; 60(1):600-8. PubMed ID: 26574011
[TBL] [Abstract][Full Text] [Related]
49. High-Throughput Screening Assays for Dengue Antiviral Drug Development.
Jabanathan SG; Xuan LZ; Ramanathan B
Methods Mol Biol; 2021; 2296():279-302. PubMed ID: 33977455
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis.
Wang QY; Bushell S; Qing M; Xu HY; Bonavia A; Nunes S; Zhou J; Poh MK; Florez de Sessions P; Niyomrattanakit P; Dong H; Hoffmaster K; Goh A; Nilar S; Schul W; Jones S; Kramer L; Compton T; Shi PY
J Virol; 2011 Jul; 85(13):6548-56. PubMed ID: 21507975
[TBL] [Abstract][Full Text] [Related]
51. Structure-guided Discovery of a Novel Non-peptide Inhibitor of Dengue Virus NS2B-NS3 Protease.
Li L; Basavannacharya C; Chan KW; Shang L; Vasudevan SG; Yin Z
Chem Biol Drug Des; 2015 Sep; 86(3):255-64. PubMed ID: 25533891
[TBL] [Abstract][Full Text] [Related]
52. Antiviral Screen against Canine Distemper Virus-Induced Membrane Fusion Activity.
Shrestha N; Gall FM; Vesin J; Chambon M; Turcatti G; Fotiadis D; Riedl R; Plattet P
Viruses; 2021 Jan; 13(1):. PubMed ID: 33477492
[TBL] [Abstract][Full Text] [Related]
53. Viral entry inhibitors block dengue antibody-dependent enhancement in vitro.
Nicholson CO; Costin JM; Rowe DK; Lin L; Jenwitheesuk E; Samudrala R; Isern S; Michael SF
Antiviral Res; 2011 Jan; 89(1):71-4. PubMed ID: 21093488
[TBL] [Abstract][Full Text] [Related]
54. A novel dengue virus inhibitor, BP13944, discovered by high-throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease.
Yang CC; Hu HS; Wu RH; Wu SH; Lee SJ; Jiaang WT; Chern JH; Huang ZS; Wu HN; Chang CM; Yueh A
Antimicrob Agents Chemother; 2014; 58(1):110-9. PubMed ID: 24145533
[TBL] [Abstract][Full Text] [Related]
55. Antiviral activity of silymarin and baicalein against dengue virus.
Low ZX; OuYong BM; Hassandarvish P; Poh CL; Ramanathan B
Sci Rep; 2021 Oct; 11(1):21221. PubMed ID: 34707245
[TBL] [Abstract][Full Text] [Related]
56. A peptide inhibitor derived from the conserved ectodomain region of DENV membrane (M) protein with activity against dengue virus infection.
Panya A; Sawasdee N; Junking M; Srisawat C; Choowongkomon K; Yenchitsomanus PT
Chem Biol Drug Des; 2015 Nov; 86(5):1093-104. PubMed ID: 25891143
[TBL] [Abstract][Full Text] [Related]
57. Labyrinthopeptin A1 inhibits dengue and Zika virus infection by interfering with the viral phospholipid membrane.
Oeyen M; Meyen E; Noppen S; Claes S; Doijen J; Vermeire K; Süssmuth RD; Schols D
Virology; 2021 Oct; 562():74-86. PubMed ID: 34274562
[TBL] [Abstract][Full Text] [Related]
58. Policresulen, a novel NS2B/NS3 protease inhibitor, effectively inhibits the replication of DENV2 virus in BHK-21 cells.
Wu DW; Mao F; Ye Y; Li J; Xu CL; Luo XM; Chen J; Shen X
Acta Pharmacol Sin; 2015 Sep; 36(9):1126-36. PubMed ID: 26279156
[TBL] [Abstract][Full Text] [Related]
59. Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate.
Schmidt AG; Yang PL; Harrison SC
PLoS Pathog; 2010 Apr; 6(4):e1000851. PubMed ID: 20386713
[TBL] [Abstract][Full Text] [Related]
60. Peptides as Therapeutic Agents for Dengue Virus.
Chew MF; Poh KS; Poh CL
Int J Med Sci; 2017; 14(13):1342-1359. PubMed ID: 29200948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
